Compass Therapeutics (CMPX) Return on Capital Employed (2019 - 2026)
Compass Therapeutics (CMPX) reported Return on Capital Employed of 37.2% for Q1 2026, up 1389.0% on a YoY basis from 2.5% in Q1 2025, and down 7.98% sequentially from 34.45% in Q4 2025.
Compass Therapeutics (CMPX) Return on Capital Employed (2019 - 2026) Analysis & Trends
Compass Therapeutics (CMPX) has 8 years of Return on Capital Employed data on file, last reported at 37.2% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1389.0% year-over-year to 37.2%; the trailing twelve-month figure through Mar 2026 stood at 37.2% (up 1389.0% YoY), and the FY2025 full-year result was 43.87%, down 336.0% from the prior year.
- Return on Capital Employed declined to 37.2% in Q1 2026, from 34.45% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 23.7% in Q1 2022 to a low of 61.56% in Q2 2025.
- A 5-year average of 35.55% and a median of 34.44% in 2024 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 8836 bps in 2022 and plunged 2452 bps in 2025, its largest moves.
- Tracing CMPX's Return on Capital Employed over 5 years: stood at 28.23% in 2022, then slipped by 15 bps to 32.36% in 2023, then declined by 29 bps to 41.67% in 2024, then increased by 17 bps to 34.45% in 2025, then declined by 8 bps to 37.2% in 2026.
- Business Quant data shows CMPX's Return on Capital Employed at 37.2% in Q1 2026, 34.45% in Q4 2025, and 44.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Compass Therapeutics | 395.17 Mn | 200.48 Mn | - | -37.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.20% |
| Dec 31, 2025 | -34.45% |
| Sep 30, 2025 | -44.21% |
| Jun 30, 2025 | -61.56% |
| Mar 31, 2025 | -51.08% |
| Dec 31, 2024 | -41.67% |
| Sep 30, 2024 | -37.48% |
| Jun 30, 2024 | -37.04% |
| Mar 31, 2024 | -34.44% |
| Dec 31, 2023 | -32.36% |
| Sep 30, 2023 | -28.92% |
| Jun 30, 2023 | -27.91% |
| Mar 31, 2023 | -24.19% |
| Dec 31, 2022 | -28.23% |
| Sep 30, 2022 | -33.56% |
| Jun 30, 2022 | -26.43% |
| Mar 31, 2022 | -23.70% |
| Dec 31, 2021 | -55.03% |
| Mar 31, 2021 | -112.06% |
| Sep 30, 2020 | -65.52% |